NVAX Stock Price: Novavax Inc drops as big name biotech companies inch closer to EUA for COVID-19 vaccine
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:NVAX falls by 4.08% amidst a broader market selloff stimulus talks stumble in America.
- Novavax teams with UC Davis Health to test its coronavirus vaccine candidate.
- COVID-19 vaccine makers watch on as Pfizer expects EUA on Thursday from the FDA.
NASDAQ:NVAX has been somewhat forgotten in the race for Emergency Use Authorization (EUA) of its COVID-19 vaccine, taking a backseat to some of the biotech giants who are anticipating approval over the next couple of weeks. Novavax dropped 4.08% on Wednesday alongside a broader market selloff as US stimulus talks hit another wall in Congress. Investors do not have much to complain about considering shares are still up nearly 3000% over the past 52-weeks, with more to come in 2021 once its COVID-19 vaccine is approved for distribution.
Novavax announced it is teaming with UC Davis Health to begin a Stage 3 clinical trial that will hopefully mean that its COVID-19 vaccine candidate NVX-CoV2373 will be approved and ready to be distributed by early to midway through 2021. For its part, Novavax has already secured some massive deals including 1 billion doses for India, whenever the vaccine can be produced. The Maryland-based biotech firm also has deals in place with Australia and Canada, amongst other countries, so 2021 could be lining up as a big year for Novavax, which still only commands a $7 billion market cap.
NVAX stock news
While Novavax is lagging behind leaders like Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), early results from its clinical trials had some analysts labelling Novavax as the company to beat in Operation Warp Speed. Pfizer and Moderna will have the first-mover advantage and are already the brands synonymous with ridding the world of COVID-19, but by the end of it, Novavax should be there as well and that is already evident in the large orders it has received.
- NASDAQ:NVAX falls by 4.08% amidst a broader market selloff stimulus talks stumble in America.
- Novavax teams with UC Davis Health to test its coronavirus vaccine candidate.
- COVID-19 vaccine makers watch on as Pfizer expects EUA on Thursday from the FDA.
NASDAQ:NVAX has been somewhat forgotten in the race for Emergency Use Authorization (EUA) of its COVID-19 vaccine, taking a backseat to some of the biotech giants who are anticipating approval over the next couple of weeks. Novavax dropped 4.08% on Wednesday alongside a broader market selloff as US stimulus talks hit another wall in Congress. Investors do not have much to complain about considering shares are still up nearly 3000% over the past 52-weeks, with more to come in 2021 once its COVID-19 vaccine is approved for distribution.
Novavax announced it is teaming with UC Davis Health to begin a Stage 3 clinical trial that will hopefully mean that its COVID-19 vaccine candidate NVX-CoV2373 will be approved and ready to be distributed by early to midway through 2021. For its part, Novavax has already secured some massive deals including 1 billion doses for India, whenever the vaccine can be produced. The Maryland-based biotech firm also has deals in place with Australia and Canada, amongst other countries, so 2021 could be lining up as a big year for Novavax, which still only commands a $7 billion market cap.
NVAX stock news
While Novavax is lagging behind leaders like Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), early results from its clinical trials had some analysts labelling Novavax as the company to beat in Operation Warp Speed. Pfizer and Moderna will have the first-mover advantage and are already the brands synonymous with ridding the world of COVID-19, but by the end of it, Novavax should be there as well and that is already evident in the large orders it has received.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.